SEC Company Response from Ayala Pharmaceuticals, Inc. (CIK 0001797336) — Jun 11, 2021
Ayala Pharmaceuticals, Inc. (CIK 0001797336)
Date: June 11, 2021 · CIK: 0001797336 · Accession: 0001193125-21-188813
AI Filing Summary & Sentiment
File numbers found in text: 333-256792
Letter
June 11, 2021
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeffrey Gabor
Re: Ayala Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 4, 2021
Registration No. 333-256792
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on June 15, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Ayala Pharmaceuticals, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Keith Halverstam of Latham & Watkins LLP, counsel to the Company, at (212) 906-1761, or in his absence, Jennifer Yoon at (617) 880-4540, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
Ayala Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 11, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor Re: Ayala Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 4, 2021 Registration No. 333-256792 Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on June 15, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Ayala Pharmaceuticals, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Keith Halverstam of Latham & Watkins LLP, counsel to the Company, at (212) 906-1761, or in his absence, Jennifer Yoon at (617) 880-4540, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Sincerely yours, Ayala Pharmaceuticals, Inc. By: /s/ Yossi Maimon Yossi Maimon Chief Financial Officer cc: Peter Handrinos Keith Halverstam